Alk Abello A/S (ALKb.CO)

ALKb.CO on Copenhagen Stock Exchange

825.00DKK
6:30am EST
Change (% chg)

kr.24.00 (+3.00%)
Prev Close
kr.801.00
Open
kr.785.00
Day's High
kr.826.00
Day's Low
kr.785.00
Volume
11,648
Avg. Vol
14,356
52-wk High
kr.974.00
52-wk Low
kr.676.00

ALKb.CO

Chart for ALKb.CO

About

Alk Abello A/S is a Denmark-based company active within the pharmaceutical industry. It is engaged in the development and marketing of pharmaceutical products for the treatment, prevention and diagnosis of allergy. Its product portfolio comprises allergy vaccines, emergency treatments and allergy diagnostics products. The... (more)

Overall

Beta: 0.45
Market Cap(Mil.): kr.7,375.29
Shares Outstanding(Mil.): 9.21
Dividend: 5.00
Yield (%): 0.62

Financials

  ALKb.CO Industry Sector
P/E (TTM): 35.73 31.76 38.72
EPS (TTM): 22.42 -- --
ROI: 7.02 15.12 14.47
ROE: 9.04 15.85 15.40
Search Stocks

BRIEF-ALK Abello Q4 total revenue up at DKK 687 mln

* Q4 total revenue 687 million Danish crowns ($102.96 million) versus 612 million crowns year ago

2:50am EST

BRIEF-Alk Abello expands partnership into South-East Asian growth markets

* Abbott will register and sell house dust mite (HDM) sublingual allergy immunotherapy (SLIT) tablet in 7 new growth markets in SE Asia

28 Jan 2016

BRIEF-ALK Abelló: Marketing authorisation for Acarizax issued in France

* Says that authorities in France have issued a marketing authorisation for ALK's new house dust mite sublingual allergy immuno-therapy tablet (slit-tablet), Acarizax Source text for Eikon:

27 Jan 2016

BRIEF-Alk Abello announces results from GRAZAX Asthma Prevention trial in children

* Announces top-line results from the five-year landmark GRAZAX Asthma Prevention (GAP) trial in children

14 Jan 2016

BRIEF-Alk Abello increases 2015 forecasts after high French sales

* Alk Abello increases 2015 forecasts due to higher sales in France

06 Jan 2016

BRIEF-Alk Abello's ACARIZAX obtains reimbursement in Denmark

* New product product (ACARIZAX) for for treatment of house dust mite allergic rhinitis and asthma obtains reimbursement in Denmark

09 Dec 2015

BRIEF-Alk Abello announces MITICURE available in Japan

* MITICURE has been placed on Japanese National Health Insurance reimbursement list and will be launched in beginning of December

26 Nov 2015

BRIEF-Alk Abello Q3 revenue including partner income up at DKK 667 million

* Q3 revenue including partner income grew by 24 percent to 667 million Danish crowns ($96.1 million) versus 522 million crowns year ago

12 Nov 2015

BRIEF-Alk Abello's partner, Torii, obtains approval for house dust mite SLIT-tablet in Japan

* Alk's partner, Torii, obtains approval for the house dust mite SLIT-tablet in Japan

28 Sep 2015

BRIEF-Alk Abello obtains European approval for HDM SLIT-tablet

* Obtains European approval for its house dust mite sublingual allergy immunotherapy tablet (HDM SLIT-tablet) against allergic rhinitis and allergic asthma

31 Aug 2015

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Reuters Investment Profile
$20.00
Provider : Wright Reports
$75.00
Provider : Thomson Reuters StreetEvents
$75.00
Provider : GlobalData
$300.00
Provider : Thomson Reuters StreetEvents
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks